[Featured Stock] Nature Cell Hits Upper Limit Early in Trading... "Jointstem Phase 3 Clinical Trial Success"
[Asia Economy Reporter Park Soyeon] Bio company Naturecell recorded a limit-up in the early morning session.
As of 9:09 a.m. on the 17th, Naturecell is trading at 15,250 won on the KOSDAQ market, up 3,500 won (29.79%) from the previous trading day.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- [Seoul, Now] Redevelopment Speed Pledge No.1: Without On-Site Insight, It Becomes the First Failure
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
On this day, Naturecell announced that "the domestic Phase 3 clinical trial of 'Jointstem,' a severe knee osteoarthritis treatment developed by Albio using the world's first autologous adipose-derived mesenchymal stem cells, has been successful."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
